The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Proteins
Completed
- Conditions
- Breast Cancer
- Registration Number
- NCT01341171
- Lead Sponsor
- University of Vermont
- Brief Summary
Single phlebotomy study involving women receiving tamoxifen or aromatase inhibitor therapy.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 30
Inclusion Criteria
- women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by their oncologist
Read More
Exclusion Criteria
- Use of heparin, warfarin
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Angiogenic Protein levels following 6 months of therapy
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Vermont
🇺🇸Burlington, Vermont, United States